Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA

NDA granted priority review Prescription Drug User Fee Act action date set for March 12, 2023 SAN DIEGO–(BUSINESS WIRE)–Sep. 12, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news